Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.45 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 9/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9428037 | 0.98 | PTGS2 (0.52) | PTGS2EPHX2CYSLTR2CYSLTR1SOAT1 | |
| SCHEMBL9560125 | 0.98 | PTGS2 (0.52) | PTGS2EPHX2CYSLTR2CYSLTR1SOAT1 | |
| SCHEMBL11443812 | 0.98 | PTGS2 (0.52) | PTGS2EPHX2CYSLTR2CYSLTR1SOAT1 | |
| SCHEMBL11434977 | 0.98 | PTGS2 (0.52) | PTGS2EPHX2CYSLTR2CYSLTR1SOAT1 | |
| SCHEMBL7721146 | 0.98 | PTGS2 (0.52) | PTGS2EPHX2CYSLTR2CYSLTR1SOAT1 | |
| SCHEMBL9428564 | 0.98 | PTGS2 (0.52) | PTGS2EPHX2CYSLTR2CYSLTR1SOAT1 | |
| SCHEMBL8595709 | 0.95 | PTGS2 (0.51) | PTGS2EPHX2CYSLTR2CYSLTR1SOAT1 | |
| SCHEMBL7760109 | 0.87 | PTGS2 (0.47) | PTGS2EPHX2SOAT1MEN1LMNA | |
| SCHEMBL19630504 | 0.83 | PTGS2 (0.50) | PTGS2EPHX2CYSLTR2CYSLTR1SOAT1 | |
| SCHEMBL7384646 | 0.83 | LMNA (0.40) | PTGS2EPHX2MEN1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE38425-E1 | ANTICONVULSANTS ADMINISTERED ORALLLY | UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES, INC. (CA) | 2004-02-10 | — | — | US | claimed |
| US-20040192680-A1 | Novel amides that activate soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-09-30 | — | — | US | disclosed |
| WO-2004060859-A2 | NOVEL AMIDES THAT ACTIVATE SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040121994-A1 | Novel amides that activate soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
| CN-1062263-C | Semicarbazones having CNS activity and pharmaceutical preparations containing same | UNIV SASKATCHEWAN (CA) | 2001-02-21 | — | — | CN | disclosed |
| CN-1190388-A | Semicarbazones having central nervous system activity and pharmaceutical preparations containing the same | UNIV SASKATCHEWAN (CA) | 1998-08-12 | — | — | CN | disclosed |
| EP-0396827-A1 | 2-Phenylthiobenzylamine dervivatives and acid addition salts thereof | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu (CS) | 1990-11-14 | — | — | EP | disclosed |
| EP-0396827-A1 | 2-Phenylthiobenzylamine dervivatives and acid addition salts thereof | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu (CS) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121994-A1 | Novel amides that activate soluble guanylate cyclase | GUCY1A1, GUCY1B1, GUCY1A2 | PTGS2 339/4885EPHX2 1442/4885CYSLTR2 1162/4885 |
| US-20040192680-A1 | Novel amides that activate soluble guanylate cyclase | GUCY1A1, GUCY1B1, GUCY1A2 | PTGS2 339/4885EPHX2 1442/4885CYSLTR2 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.